JP2016529235A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2016529235A5 JP2016529235A5 JP2016526992A JP2016526992A JP2016529235A5 JP 2016529235 A5 JP2016529235 A5 JP 2016529235A5 JP 2016526992 A JP2016526992 A JP 2016526992A JP 2016526992 A JP2016526992 A JP 2016526992A JP 2016529235 A5 JP2016529235 A5 JP 2016529235A5
- Authority
- JP
- Japan
- Prior art keywords
- optionally
- amino
- group
- alkyl
- substituted
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361846787P | 2013-07-16 | 2013-07-16 | |
| US61/846,787 | 2013-07-16 | ||
| PCT/US2014/046203 WO2015009545A1 (en) | 2013-07-16 | 2014-07-10 | Derivatives of n-urea substituted amino acids as formyl peptide receptor modulators |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2016529235A JP2016529235A (ja) | 2016-09-23 |
| JP2016529235A5 true JP2016529235A5 (cg-RX-API-DMAC10.html) | 2017-08-17 |
| JP6653253B2 JP6653253B2 (ja) | 2020-02-26 |
Family
ID=51230227
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016526992A Expired - Fee Related JP6653253B2 (ja) | 2013-07-16 | 2014-07-10 | ホルミルペプチド受容体モジュレーターとしてのｎ−尿素置換アミノ酸の誘導体 |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US9428549B2 (cg-RX-API-DMAC10.html) |
| EP (1) | EP3022174B1 (cg-RX-API-DMAC10.html) |
| JP (1) | JP6653253B2 (cg-RX-API-DMAC10.html) |
| KR (1) | KR102313757B1 (cg-RX-API-DMAC10.html) |
| CN (1) | CN105377814B (cg-RX-API-DMAC10.html) |
| AU (1) | AU2014290618B2 (cg-RX-API-DMAC10.html) |
| CA (1) | CA2917811C (cg-RX-API-DMAC10.html) |
| DK (1) | DK3022174T3 (cg-RX-API-DMAC10.html) |
| ES (1) | ES2708571T3 (cg-RX-API-DMAC10.html) |
| RU (1) | RU2696581C2 (cg-RX-API-DMAC10.html) |
| WO (1) | WO2015009545A1 (cg-RX-API-DMAC10.html) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2012329098B2 (en) | 2011-10-26 | 2017-08-03 | Allergan, Inc. | Amide derivatives of N-urea substituted amino acids as formyl peptide receptor like-1 (FPRL-1) receptor modulators |
| BR112015021392B1 (pt) * | 2013-03-06 | 2021-11-16 | Allergan, Inc | Uso de agonistas do receptor de peptídeo formil 2 para tratar doenças dermatológicas |
| AU2014352922B2 (en) | 2013-11-21 | 2018-06-07 | Allergan, Inc. | Phenylcarbamate derivatives as formyl peptide receptor modulators |
| SI3075726T1 (en) | 2013-11-28 | 2018-05-31 | Kyorin Pharmaceutical Co., Ltd. | DERIVATIVES OF UREA OR ITS PHARMACOLOGICAL RECRUITABLE SALTS USED AS FORMIL PEPTIDAL RECEPTOR LIKE 1 (FPRL-1) AGONISTS |
| US9663457B2 (en) | 2014-04-09 | 2017-05-30 | Allergan, Inc. | Carbamoyl hydrazine derivatives as formyl peptide modulators |
| CN106458921B (zh) | 2014-05-21 | 2020-03-24 | 阿勒根公司 | 作为甲酰肽受体调节剂的咪唑衍生物 |
| EP3303284B1 (en) | 2015-05-27 | 2020-04-08 | Kyorin Pharmaceutical Co., Ltd. | Urea derivative or pharmacologically acceptable salt thereof |
| AR104751A1 (es) | 2015-05-27 | 2017-08-09 | Kyorin Seiyaku Kk | Derivado de urea o una sal de este aceptable desde el punto de vista farmacológico |
| CA2992662A1 (en) * | 2015-08-05 | 2017-02-09 | Allergan, Inc. | Phenyl urea analogs as formyl peptide repceptor 1 (fpr1) selective agonists |
| HUE058044T2 (hu) | 2018-03-05 | 2022-06-28 | Bristol Myers Squibb Co | Fenilpirrolidinon-formil peptid 2 receptor agonisták |
Family Cites Families (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2533210A1 (fr) | 1982-09-17 | 1984-03-23 | Lyon I Universite Claude | Edulcorants de synthese |
| US5284828A (en) | 1990-05-14 | 1994-02-08 | Fujisawa Pharmaceutical Co. Ltd. | Peptide compound and its preparation |
| JP3387948B2 (ja) * | 1992-12-04 | 2003-03-17 | 富山化学工業株式会社 | 新規なフェニルアラニン誘導体またはその塩 |
| US20030009022A1 (en) * | 1993-03-31 | 2003-01-09 | Cadus Pharmaceutical Corporation | Methods and compositions for identifying receptor effectors |
| JP2968842B2 (ja) * | 1994-02-09 | 1999-11-02 | 塩野義製薬株式会社 | カルバモイルメチルウレア誘導体 |
| CA2181986A1 (en) * | 1994-02-09 | 1995-08-17 | Sanji Hagishita | Carbamoylmethylurea derivatives |
| US6423689B1 (en) * | 1997-12-22 | 2002-07-23 | Warner-Lambert Company | Peptidyl calcium channel blockers |
| WO1999065932A1 (en) * | 1998-06-18 | 1999-12-23 | Sepracor, Inc. | Tetrapeptides, analogs and peptidomimetics which bind selectively mammalian opioid receptors |
| US20050164305A1 (en) * | 2002-04-03 | 2005-07-28 | Bayer Healthcare Ag | Diagnostics and therapeutics for diseases associated with n-formyl peptide receptor like 1 (fprl1) |
| WO2005047899A2 (en) * | 2003-11-07 | 2005-05-26 | Acadia Pharmaceuticals Inc. | Use of the lipoxin receptor, fprl1, as a tool for identifying compounds effective in the treatment of pain and inflammation |
| ES2431298T3 (es) * | 2009-05-18 | 2013-11-25 | Actelion Pharmaceuticals Ltd. | Derivados de espiro[2.4]heptano puenteados como agonistas del receptor de ALX y/o FPRL2 |
| CA2819457A1 (en) * | 2010-12-03 | 2012-06-07 | Allergan, Inc. | Pharmaceutical compositions comprising 3,4-dihydroisoquinolin-2(1h)-yl-3-phenylurea derivatives having formyl peptide receptor like-1 (fprl-1) agonist or antagonist activity |
| AU2012329098B2 (en) * | 2011-10-26 | 2017-08-03 | Allergan, Inc. | Amide derivatives of N-urea substituted amino acids as formyl peptide receptor like-1 (FPRL-1) receptor modulators |
| US8541577B2 (en) * | 2011-11-10 | 2013-09-24 | Allergan, Inc. | Aryl urea derivatives as N-formyl peptide receptors like-1 (FPRL-1) receptor modulators |
| US8735622B2 (en) * | 2011-11-30 | 2014-05-27 | The Regents Of The University Of Colorado, A Body Corporate | Histone demethylase inhibitors and methods for using the same |
| BR112015021392B1 (pt) * | 2013-03-06 | 2021-11-16 | Allergan, Inc | Uso de agonistas do receptor de peptídeo formil 2 para tratar doenças dermatológicas |
| BR122017004254B1 (pt) * | 2013-03-06 | 2021-04-13 | Allergan, Inc. | Uso de agonistas de receptor de formil peptídeo 2 para tratar doenças inflamatórias oculares |
-
2014
- 2014-07-10 ES ES14744725T patent/ES2708571T3/es active Active
- 2014-07-10 EP EP14744725.4A patent/EP3022174B1/en active Active
- 2014-07-10 DK DK14744725.4T patent/DK3022174T3/da active
- 2014-07-10 CA CA2917811A patent/CA2917811C/en active Active
- 2014-07-10 AU AU2014290618A patent/AU2014290618B2/en not_active Ceased
- 2014-07-10 CN CN201480040132.5A patent/CN105377814B/zh not_active Expired - Fee Related
- 2014-07-10 KR KR1020167003770A patent/KR102313757B1/ko not_active Expired - Fee Related
- 2014-07-10 WO PCT/US2014/046203 patent/WO2015009545A1/en not_active Ceased
- 2014-07-10 JP JP2016526992A patent/JP6653253B2/ja not_active Expired - Fee Related
- 2014-07-10 RU RU2016104844A patent/RU2696581C2/ru active
- 2014-07-10 US US14/328,540 patent/US9428549B2/en active Active